Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00089570 · ClinicalTrials.gov registry record · Phase 3
Study of Terlipressin Versus Placebo to Treat Hepatorenal Syndrome Type 1
A Phase 3 study, sponsored by Mallinckrodt.
- Completed
- Registry status
- Phase 3
- Development phase
- 112
- Enrollment target
NCT00089570 is a Phase 3 study that has completed, run by Mallinckrodt. The registered enrollment target is 112 participants.
The verdict
NCT00089570, a Phase 3 study, has completed, sponsored by Mallinckrodt.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 112 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether terlipressin is safe and effective in the treatment of patients with hepatorenal syndrome (HRS) type 1 when compared to placebo.
Interventions
- DRUG Placebo
- DRUG terlipressin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 112 participants |
| Start Date | 2004-06 |
| Est. Completion | 2006-09 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00089570
The ClinicalTrials.gov registry entry for NCT00089570 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 112 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mallinckrodt, which has 69 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00089570 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00089570 about?
NCT00089570 is a clinical study titled "Study of Terlipressin Versus Placebo to Treat Hepatorenal Syndrome Type 1". The purpose of this study is to determine whether terlipressin is safe and effective in the treatment of patients with hepatorenal syndrome (HRS) type 1 when compared to placebo.
What is the current status of trial NCT00089570?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 112 participants. The study started on 2004-06. Estimated completion is 2006-09.
What interventions are being tested in trial NCT00089570?
The interventions under investigation include: Placebo (DRUG), terlipressin (DRUG).
Who is sponsoring clinical trial NCT00089570?
This trial is sponsored by Mallinckrodt, which has 69 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.